Clinical trial · no report yet · Phase 2

ENCO-BRAF

ENCOrafenib With Binimetinib in bRAF NSCLC

NCT04526782 ↗
Active, not recruiting
Intergroupe Francophone de Cancerologie Thoracique
Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	11
Podcasts	1

The trial

ClinicalTrials.gov

Official title: A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer
Phase: Phase 2
Status: Active, not recruiting
Conditions: Non Small Cell Lung Cancer; BRAF V600E
Interventions: Encorafenib 75 MG; Binimetinib 15 MG
Arms: Cohort 1 (1st line) · Experimental
Cohort 2 (2nd line) · Experimental
Enrollment: 119 (estimated)
Primary outcomes: Objective response rate
Sponsor: Intergroupe Francophone de Cancerologie Thoracique
Start: Jan 19, 2021
Primary completion: Jul 16, 2025
Results posted: No
Registry record: NCT04526782 · updated Aug 11, 2026